HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Stock Performance

ACXP traded down $0.04 on Tuesday, hitting $1.30. The company had a trading volume of 154,980 shares, compared to its average volume of 1,112,300. The stock has a market capitalization of $7.23 million, a price-to-earnings ratio of -0.48 and a beta of -2.02. The stock has a fifty day moving average price of $1.43 and a 200-day moving average price of $2.08. Acurx Pharmaceuticals has a 12-month low of $1.27 and a 12-month high of $8.34.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). Analysts forecast that Acurx Pharmaceuticals will post -2 EPS for the current fiscal year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.